MAPT and Alzheimer disease: Compared with CH individuals with normal CSF Aβ42/tau ratios (CH-NATs), CH individuals with pathological Aβ42/tau ratios (CH-PATs) are at a greater risk of cognitive deterioration to MCI or AD.